Could a simple supplement slow ALS? new trial aims to find out

This completed Phase 2 pilot trial tested whether personalized supplements could slow the progression of ALS. Researchers used a genetic analysis platform to sort 50 participants into four disease categories—neuroinflammation, oxidative stress, impaired autophagy, or mitochondrial dysfunction—and gave each group a specific supplement (astaxanthin, protandim, melatonin, or MitoQ) for six months. The goal was to see if these supplements could slow decline in daily function, as measured by the ALS Functional Rating Scale.